ProMIS Neurosciences, Inc. (PMN) Income Statement
PMN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPMN revenue and net income
PMN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | −1,529.3% | — | — | — |
| EPS (diluted) | −186,033.3% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PMN quarterly EPS vs estimates
ProMIS Neurosciences beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 11, 2026 (estimate $-1.26).
PMN income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of revenue | $33.4M | — | $10.4M |
| Gross profit | −$33.4M | — | −$10.4M |
| Research & development | $33.4M | $10.6M | $7.9M |
| Sales, general & admin | $6.8M | $6.2M | $7.4M |
| Total operating expenses | $40.2M | $16.8M | $8.5M |
| Operating income | −$40.2M | −$16.8M | −$18.9M |
| Interest expense | $0 | $76,775 | $201,390 |
| Income before taxes | −$39.7M | $2.8M | −$17.5M |
| Income taxes | — | — | −$167,895 |
| Net income | −$39.7M | $2.8M | −$17.5M |
| EBITDA | −$39.7M | $2.9M | −$17.8M |
| EPS (diluted) | −$55.78 | $0.03 | −$7.66 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $6,275 | $0 |
| Cost of revenue | — | — | $9.4M | — | — | — | $4.3M | $3.5M | $2.2M | $18,021 | — |
| Gross profit | — | — | −$9.4M | — | — | — | −$4.3M | −$3.5M | −$2.2M | −$18,021 | — |
| Research & development | $9.5M | $7.0M | $9.4M | $9.8M | $8.7M | $5.5M | $4.3M | $2.6M | $1.6M | $2.1M | $2.2M |
| Sales, general & admin | $2.7M | $1.7M | $1.4M | $2.0M | $1.4M | $2.0M | $1.7M | $1.9M | $1.1M | $1.6M | $1.6M |
| Total operating expenses | $12.3M | $8.6M | $10.8M | $11.8M | $10.2M | $7.5M | $6.0M | $4.4M | $2.7M | $3.7M | $3.9M |
| Operating income | −$12.3M | −$8.6M | −$10.8M | −$11.8M | −$10.2M | −$7.5M | −$6.0M | −$4.4M | −$2.7M | −$3.7M | −$3.9M |
| Interest expense | — | — | $0 | $0 | $0 | $0 | $76.9M | $0 | $0 | $76,775 | $76,795 |
| Income before taxes | −$11.7M | −$8.2M | −$10.7M | −$11.6M | −$10.1M | −$7.3M | −$238,207 | $9.3M | −$2.6M | −$3.6M | −$3.6M |
| Income taxes | — | — | — | — | — | — | — | — | — | −$7,166 | — |
| Net income | −$11.7M | −$8.2M | −$10.7M | −$11.6M | −$10.1M | −$7.3M | −$238,207 | $9.3M | −$2.6M | −$3.6M | −$3.6M |
| EBITDA | −$11.7M | −$8.6M | −$10.8M | −$11.6M | −$10.1M | −$7.3M | −$6.0M | $9.3M | −$2.6M | −$3.6M | — |
| EPS (diluted) | −$1.28 | −$1.26 | −$30.05 | −$8.40 | −$9.98 | −$7.35 | $0.12 | $10.86 | −$4.47 | −$6.48 | −$0.29 |
| Gross margin | — | — | — | — | — | — | — | — | — | −287.2% | — |
| Operating margin | — | — | — | — | — | — | — | — | — | −58,592.0% | — |
| Net margin | — | — | — | — | — | — | — | — | — | −57,929.7% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PMN's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PMN financial results
ProMIS Neurosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $39.7 million. Diluted earnings per share came to −$55.78.
See the PMN stock overview for the latest quote and news, or the PMN chart for price history and technical indicators.
PMN income statement FAQ
Does ProMIS Neurosciences have revenue?
ProMIS Neurosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is ProMIS Neurosciences profitable?
No. ProMIS Neurosciences reported a net loss of $39.7 million in fiscal 2025.
How much does ProMIS Neurosciences spend on research and development?
ProMIS Neurosciences spent $33.4 million on research and development in fiscal 2025.
What are ProMIS Neurosciences's earnings per share?
ProMIS Neurosciences earned $-55.78 per diluted share in fiscal 2025, compared with $0.03 a year earlier.
When will ProMIS Neurosciences report its next earnings?
ProMIS Neurosciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does ProMIS Neurosciences's fiscal year end?
ProMIS Neurosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.